GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.
Business Wire•05/10/2026•08:00 ET
0
Key Highlights
- ➤GE HealthCare to acquire SOFIE Biosciences for $945 million in cash
- ➤SOFIE operates 15 U.S. sites with 21 cyclotrons and a theranostics CDMO site
- ➤Transaction expected to close in first half of 2027, pending regulatory approvals
- ➤GE HealthCare gains U.S. rights to Phase III FAPI-74 PET radiotracer
- ➤Deal expected to be accretive to revenue growth, adjusted EBIT margin and adjusted EPS
Expert Statements
Kevin O'Neill, President & CEO of the PDx segment at GE HealthCare
“The PET radiopharmaceutical market is expanding rapidly with the introduction of innovative radiotracers and advances in precision care, including the growing adoption of targeted therapies. As part of GE HealthCare, SOFIE Biosciences is expected to grow in the low double digits, and enables us to participate across the radiopharmaceutical value stream, meeting customer demand through a mix of GE HealthCare owned and partner facilities. SOFIE Biosciences has a highly skilled team with deep expertise serving U.S. customers, including manufacturing our Flyrcado™ (flurpiridaz F18 injection) product.”
Kevin O'Neill, President & CEO of the PDx segment at GE HealthCare
“We will leverage our scale and expertise in radiopharmaceutical manufacturing across the U.S., Europe and Japan to further invest in and grow SOFIE Biosciences, helping improve patient access, strengthen reliability of supply, and support the next generation of precision care products.”
Patrick Phelps, Co-founder, President & CEO of SOFIE Biosciences
“As demand continues to increase for F18 products, and pipelines for new diagnostics and therapeutics continue to expand, joining GE HealthCare marks an exciting step in our journey as a leading U.S. CMO. With Trilantic North America’s support, we have significantly expanded our capabilities and scale, and we share GE HealthCare’s ambition to improve patient outcomes by delivering on the promise of radiopharmaceuticals as we look ahead to our next phase of growth.”
Ted Rosenwasser, Partner, Trilantic North America
“We are incredibly proud of what Patrick and the SOFIE Biosciences team have accomplished during our partnership. SOFIE Biosciences has grown significantly, investing in its network and manufacturing capabilities to help meet growing demand and enable increased and reliable patient access to critical products. GE HealthCare's legacy and global expertise make it a natural partner to support SOFIE Biosciences’ continued growth and help expand access for U.S. patients to novel diagnostic and therapeutic radiopharmaceuticals.”
GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.
* Broadens GE HealthCare's footprint in the U.S. radiopharmaceutical industry, drives patient access to F18 labeled Positron Emission Tomography (PET) radiopharmaceuticals and enhances exposure to new high-growth areas
Get started
Create a free account to read the full story.